Alterations in both cell metabolism and transcriptional programs are hallmarks of cancer that sustain rapid proliferation and metastasis 1 . However, the mechanisms that control the interaction between metabolic reprogramming and transcriptional regulation remain unclear. Here we show that the metabolic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) regulates transcriptional reprogramming by activating the oncogenic steroid receptor coactivator-3 (SRC-3). We used a kinome-wide RNA interference-based screening method to identify potential kinases that modulate the intrinsic SRC-3 transcriptional response. PFKFB4, a regulatory enzyme that synthesizes a potent stimulator of glycolysis 2 , is found to be a robust stimulator of SRC-3 that coregulates oestrogen receptor. PFKFB4 phosphorylates SRC-3 at serine 857 and enhances its transcriptional activity, whereas either suppression of PFKFB4 or ectopic expression of a phosphorylationdeficient Ser857Ala mutant SRC-3 abolishes the SRC-3-mediated transcriptional output. Functionally, PFKFB4-driven SRC-3 activation drives glucose flux towards the pentose phosphate pathway and enables purine synthesis by transcriptionally upregulating the expression of the enzyme transketolase. In addition, the two enzymes adenosine monophosphate deaminase-1 (AMPD1) and xanthine dehydrogenase (XDH), which are involved in purine metabolism, were identified as SRC-3 targets that may or may not be directly involved in purine synthesis. Mechanistically, phosphorylation of SRC-3 at Ser857 increases its interaction with the transcription factor ATF4 by stabilizing the recruitment of SRC-3 and ATF4 to target gene promoters. Ablation of SRC-3 or PFKFB4 suppresses breast tumour growth in mice and prevents metastasis to the lung from an orthotopic setting, as does Ser857Ala-mutant SRC-3. PFKFB4 and phosphorylated SRC-3 levels are increased and correlate in oestrogen receptor-positive tumours, whereas, in patients with the basal subtype, PFKFB4 and SRC-3 drive a common protein signature that correlates with the poor survival of patients with breast cancer. These findings suggest that the Warburg pathway enzyme PFKFB4 acts as a molecular fulcrum that couples sugar metabolism to transcriptional activation by stimulating SRC-3 to promote aggressive metastatic tumours.
. Importantly, dynamic interactions between SRC-3 and its subsequent recruitment to target genes are delicately regulated by post-translational modifications on SRC-3 6 . Phosphorylation of SRC-3 can alter its transcriptional activity, protein stability and subcellular localization [7] [8] [9] , and deregulated kinase signalling hyperactivating SRC-3 is a hallmark of many tumours 10, 11 . As a starting point for identifying kinases that modulate SRC-3 transcriptional activity, we performed an unbiased RNA interference (RNAi) screening assay using a kinome library containing short interfering RNAs (siRNAs) that target 636 human kinases (median 3 siRNAs per kinase) in the presence of a GAL4-DNA binding domain-fused SRC-3 (pBIND-SRC-3) 12 and GAL4 DNA-binding sites containing the luciferase reporter gene (pG5-luc) (Fig. 1a) . The concentration of the pBIND-SRC-3 construct needed to obtain luciferase readings in a linear range was standardized along with the dose of kinase siRNAs to observe significant alterations in SRC-3 intrinsic activity (Extended Data Fig. 1a, b) . As a positive control, we used siRNAs that target PRKCZ1, a protein kinase known to activate SRC-3 13 , and compared the repression of the coregulator activity after kinase knockdown with non-targeting control green fluorescent protein (GFP) siRNAs (Extended Data Fig. 1c ). Kinome-wide screening identified several kinases as modulators of SRC-3 activity ( Ten kinases were designated as reproducible and significant hits in the screen (Fig. 1c and Extended Data Fig. 1f ), among which metabolic kinase PFKFB4 was identified as the most robust positive regulator of SRC-3 activity. A secondary screen coupled with growth assays to identify the top-hit kinases that drive cancer cell proliferation also identified PFKFB4 as the most dominant kinase that regulates cellular proliferation (Extended Data Fig. 1g ). Silencing of PFKFB4 with different short hairpin RNAs (shRNAs) and siRNAs decreased SRC-3 activity (Extended Data Fig. 2a , b) in several cancer lines with reduced PFKFB4 levels (Extended Data Fig. 2c, d ), whereas ectopic overexpression of PFKFB4 using adenoviral infection (ad-PFKFB4) enhanced SRC-3 activity (Fig. 1d) . Interestingly, SRC-3 protein levels were increased after ectopic PFKFB4 expression (Fig. 1e ), but SRC-3 (also known as NCOA3) mRNA levels were not affected (Extended Data Fig. 2e ), and proximity ligation assays support a direct interaction between SRC-3 and PFKFB4, consistent with PFKFB4-dependent regulation of SRC-3 activity (Extended Data Fig. 2f ).
PFKFB4 is a bifunctional metabolic enzyme that synthesizes fructose 2,6-bisphosphate (F2,6-BP), an important sugar-phosphate metabolite that stimulates glycolysis 14 . PFKFB4 dovetails two antagonistic properties involving a kinase reaction synthesizing F2,6-BP from fructose-6-phosphate (F6P) and ATP, and conversely hydrolysing F2,6-BP into F6P and inorganic phosphate (P i ) via its phosphatase activity Letter reSeArCH a phosphate group from ATP. To confirm this observation, we performed a kinase assay using [γ- (Fig. 2a) . To identify the phosphorylation site(s) on SRC-3, we used recombinant glutathione S-transferase (GST)-fused SRC-3 fragments encoding various domains (Extended Data Fig. 3c ) as substrates for an in vitro kinase reaction, and found that only the CBPinteracting domain (CID) of 17 is phosphorylated by PFKFB4 (Fig. 2b) . In vitro phosphorylated GST-SRC-3-CID protein was then analysed by mass spectrometry, and only one serine residue (Ser857) was identified as a phosphorylation target of PFKFB4 (Extended Data Fig. 3d ). Consistent with this identification, mutation of Ser857 to alanine (Ser857Ala) abolished the phosphorylation of SRC-3-CID by PFKFB4 in vitro (Extended Data Fig. 3e ), confirming that PFKFB4 phosphorylates oncogenic coregulator SRC-3 at Ser857.
Because increased glucose metabolism stimulates the kinase activity of PFKFB4 required to maintain steady glycolysis 18 , we measured the levels of phosphorylated SRC-3 (pSRC-3) under these conditions. HEK293T cells were transfected with Flag-tagged SRC-3 and PFKFB4, and then stimulated with an increasing concentration of glucose in culture medium, which revealed enhanced phosphorylation of SRC-3 ( Fig. 2c) . Next we investigated the levels of pSRC-3-S857 in breast cancer cells under conditions of active glycolysis by immunoblotting with a pSRC-3-Ser857-antibody. MDA-MB-231 cells growing under a normal glucose condition (25 mM) showed robust phosphorylation of SRC-3 at Ser857 compared to tumour cells cultured in low glucose conditions (5 mM) (Fig. 2d) . Withdrawing glucose from the medium after growth in normal glucose conditions (25 mM) resulted in significant loss of SRC-3 phosphorylation (Fig. 2d) . Moreover, stable knockdown of PFKFB4 using two different shRNA constructs (shPFK#09 and shPFK#20) ( Fig. 2d and Extended Data Fig. 3f ) abolished pSRC-3-Ser857 levels in breast cancer cells cultured in 25 mM glucose, indicating that PFKFB4-dependent SRC-3 phosphorylation on Ser857 is a highly selective modification under conditions conducive to active glycolysis. We expressed the phosphorylation-defective mutant SRC-3(Ser857Ala) or wild-type SRC-3 protein in SRC-3-ablated cells, and under conditions of active glycolysis the levels of pSRC-3-Ser857 are increased in wild-type SRC-3 cells compared to the SRC-3(Ser857Ala) mutant cells (Extended Data Fig. 3g) . Importantly, the introduction of fructose-1,6-bisphosphate (FBP) alone into glucose-starved cells permeabilized with streptolysin O rescued pSRC-3-Ser857 levels (Extended Data Fig. 3h ), indicating that this phosphorylation event is linked to the energy status of the cell 19 .
To measure the importance of this modification on the intrinsic activity of SRC-3, we transduced cancer cells with adenovirus expressing PFKFB4 (ad-PFKFB4) or control GFP, and cultured the transduced cells in the presence of normal glucose (25 mM) or low glucose (5 mM) levels. Enhanced expression of PFKFB4 along with glucose stimulation significantly increased the transcriptional activity of SRC-3 (pBIND-SRC-3) compared to cells cultured in low glucose conditions, suggesting that PFKFB4-dependent SRC-3 phosphorylation is important for the coactivator-driven transcriptional response (Extended Data Fig. 3i ). To substantiate this observation, we used the phosphorylation-deficient pBIND-SRC-3(Ser857Ala) mutant or the phosphorylation-mimic pBIND-SRC-3(Ser857Glu) mutant in a similar transcriptional activation assay and found that the Ser857Ala mutant was significantly refractory to glucose-dependent PFKFB4 signalling (Fig. 2e) . The Ser857Glu mutant was constitutively active even at low levels of glucose, and glucose stimulation failed to show any further activation (Extended Data Fig. 4a ). Previous studies have identified several crucial sites in the kinase domain of PFKFB4 that are important for ATP binding 14 . When mutated to alanine, residues Gly46, Pro48, Gly51, Arg229 and Arg237 significantly decrease the binding affinity for ATP and result in reduced PFKFB4 kinase activity. We expressed these mutants in PFKFB4-silenced breast cancer cells and transcriptional assays confirmed significantly reduced SRC-3 activity and Ser857 phosphorylation (Extended Data Fig. 4b, c) . Because SRC-3 is an established oestrogen receptor (ER) coactivator, we investigated the importance of glucose-dependent PFKFB4 signalling on ER-mediated transcriptional activity. MCF-7 cells stably expressing an oestradiol (E2)-ER-dependent luciferase reporter gene (ERE-MAR-Luc cells) 20 were used to assay ER activity as a function of E2 and glucose in the medium. Glucose addition enhanced ER activity, whereas low glucose or SRC-3 silencing significantly repressed transcriptional output in response to E2 (Extended Data Fig. 4d ). Overexpression of PFKFB4 enhanced ER activity only in cells treated with E2 and glucose, whereas this PFKFB4-dependent increase in ER activity is repressed upon SRC-3 ablation (Extended Data Fig. 4e ). Consistent with this observation, the SRC-3(Ser857Ala) mutant failed to rescue the growth of Letter reSeArCH SRC-3-depleted cells compared to wild-type SRC-3 (Extended Data Fig. 4f ). These findings suggest that in glycolytic breast tumours, PFKFB4 and SRC-3 can also hyperactivate ER activity in the presence of E2, and phosphorylation of SRC-3 at Ser857 is a critical mark required for transcriptional responses. PFKFB4 is an important regulator of glucose metabolism and directs metabolic pathways required for biosynthesis of macromolecules to sustain rapid proliferation in cancer cells 2 . To identify the physiological role of PFKFB4-dependent SRC-3 activation in tumour metabolism, we performed an unbiased phenotypic screen to identify the metabolites that are preferentially used by SRC-3-overexpressing cells. For this we used a phenotype microarray analysis 21 containing 93 metabolites (Supplementary Table 2 ) arrayed in a microplate and measured in real-time the importance of these metabolites in supporting SRC-3-dependent growth. We transduced mammary epithelial MCF10A cells (with relatively low endogenous SRC-3) with adenovirus expressing GFP or SRC-3 followed by the phenotype screen for 24 h. We identified enhanced proliferation of cells with gain-in SRC-3 expression under conditions of glucose and purines such as adenosine and inosine (Extended Data Fig. 5a-d) . To investigate the role of SRC-3 further and determine how activation by PFKFB4 affects its regulation of metabolism in breast cancer cells, we performed mass spectrometry-based metabolic profiling of MDA-MB-231 cells expressing shRNAs that target SRC-3 or PFKFB4. Ablation of either SRC-3 or PFKFB4 significantly reduced the intracellular pools of ribose-5P (R5P), and purine nucleotides and intermediates, such as adenosine, xanthine and guanine ( Fig. 3a and Extended Data Fig. 5e, f) . Overexpression of SRC-3 in MCF10A cells also confirmed increased pools of purines (Extended Data Fig. 5g ). To measure the direct contribution of PFKFB4 and SRC-3 regulation of glucose flux towards the pentose phosphate pathway (PPP), we used isotopelabelled [6- 13 C]glucose to trace the carbon flow 22 . PFKFB4 and SRC-3 depletion significantly reduced the 13 C-enrichment of ribulose-5P/xylulose-5P, important intermediary metabolites in the PPP and rate-limiting precursors for purine biosynthesis (Extended Data Fig. 6a ). We investigated whether exogenous addition of purines could rescue the reduced growth rate of SRC-3-deficient breast cancer cells. As expected, loss of SRC-3 suppressed the growth of MDA-MB-231 and MCF-7 breast cancer cells 23 , whereas supplementation of purines in the culture medium significantly rescued the growth defect, indicating that SRC-3 expression is crucial for the synthesis of purines for growth (Fig. 3b) .
To identify the potential mechanisms of apparent SRC-3-driven purine synthesis, we performed gene expression analysis of enzymes involved in the PPP and purine synthesis. Knockdown of SRC-3 reduced the mRNA expression of transketolase (TKT), adenosine monophosphate deaminase 1 (AMPD1), and xanthine dehydrogenase (XDH) (Extended Data Fig. 6b, c) . These SRC-3 target genes were also found to be regulated by PFKFB4 knockdown (Fig. 3c) and their expression was significantly enhanced in actively glycolytic breast cancer cells (Extended Data Fig. 6d ). TKT is a major enzyme mediating nonoxidative PPP, whereas XDH and AMPD1 traditionally known to regulate purine catabolism are found to be regulated by SRC-3 24, 25 . Whether the switch in roles by these reversible enzymes XDH and AMPD1 depend on tumour metabolic state needs further investigation. Similarly, [6] [7] [8] [9] [10] [11] [12] [13] C]glucose isotope-tracing experiments also confirmed reduced levels of TKT products seduheptulose-7P (S7P) and erythrose-4P (E4P) upon PFKFB4 or SRC-3 knockdown (Extended Data Fig. 6e, f) . cultured in 25 mM glucose for 24 h and then switched to 5 mM glucose for 6 h. Protein levels of pSRC-3-Ser857, PFKFB4 and β-actin were detected by immunoblotting. e, HEK293T cells expressing pBIND, pBIND-SRC-3 or pBIND-SRC-3(Ser857Ala) were transduced with adenoviruses expressing GFP or PFKFB4, and cultured in 5 mM or 25 mM glucose followed by luciferase assay. Boxes represent the twenty-fifth and seventyfifth percentiles, lines represent median, whiskers showing minimum and maximum points, and plus symbol indicates the mean. n = 6 biologically independent experiments. ****P < 0.000001, two-way ANOVA with Tukey's multiple comparisons test. Data in a-e are representative of three biologically independent experiments with similar results. See Source Data for exact P values.
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To confirm that these genes are direct targets of SRC-3, we re-expressed SRC-3 in MDA-MB-231 cells with depleted levels of endogenous SRC-3 protein (Extended Data Fig. 3g ) and observed significant restoration of SRC-3 target genes (Extended Data Fig. 7a ). The addition of exogenous purines also restored the primary growth defects in PFKFB4-silenced MDA-MB-231 cells (Extended Data Fig. 7b) , with a decreased incorporation of [U- 13 C]glucose carbon into purines (Extended Data Fig. 7c) . Although the metabolic effects may or may not be directly regulated by target genes AMPD1 or XDH, our findings indicate that PFKFB4 and SRC-3 mutually cooperate to drive glucose flux towards purine generation.
To define how PFKFB4 phosphorylation of SRC-3 affects transcriptional regulation of the three commonly regulated purine biosynthesis genes defined above, we analysed the chromatin occupancy of SRC-3 on the promoters of TKT, XDH and AMPD1 using an existing in silico analysis of SRC-3 chromatin immunoprecipitation followed by sequencing (ChIP-seq) dataset 26 . We identified strong overlap of SRC-3 occupancy with activating transcription factor 4 (ATF4)-binding sites 27 on the three target genes (Extended Data Fig. 8a, b) . Interestingly, ATF4 has been recently identified to promote purine synthesis in response to growth signals 28 . To validate whether SRC-3 interacts with ATF4, we immunoprecipitated ATF4 from MDA-MB-231 cells growing in either 25 mM or 5 mM glucose. Under conditions of enhanced glycolysis, the interaction of ATF4 with pSRC-3-Ser857 increased robustly although the total ATF4 protein level was lower owing to reduced nutrient stress compared to 5 mM glucose treatment. However, the loss of PFKFB4, SRC-3, or re-expression of SRC-3(Ser857Ala) in SRC-3-knockdown cancer cells greatly reduced the association (Fig. 3d) . Next we performed ChIP and quantitative PCR (ChIP-qPCR) to measure the chromatin occupancy of ATF4, pSRC-3-Ser857 and SRC-3 on the target gene promoters. Breast cancer cells growing in the presence of 25 mM glucose showed increased occupancy of ATF4 and pSRC-3-Ser857 on TKT (Fig. 3e) , XDH (Extended Data Fig. 8c ) and AMPD1 ( Fig. 3f) promoters, whereas the loss of SRC-3 or PFKFB4 significantly reduced ATF4 chromatin occupancy on AMPD1 (Extended Data Fig. 8d ). In addition, we found SRC-3 recruitment to the gene promoters is dependent on ATF4, as knockdown of ATF4 significantly reduced target gene expression and pSRC-3-Ser857 promoter occupancy (Extended Data Fig. 8e, f ). These findings demonstrate that in actively glycolytic breast cancers, PFKFB4-dependent phosphorylation of SRC-3 at Ser857 promotes interaction with the transcription factor ATF4, thereby stabilizing the complex on chromatin and driving transcription of key metabolic enzymes.
To study whether suppression of PFKFB4 or SRC-3 can affect the growth of breast tumours in vivo (Fig. 4a) , we implanted MDA-MB-231 cells stably expressing non-targeting shRNA, SRC-3 shRNA (Extended Data Fig. 3g ) and PFKFB4 shRNA (Fig. 2d) into the mammary fat pad of female nude mice. Compared to control mice, genetic loss of SRC-3 or PFKFB4 exhibited substantially reduced tumour growth and volume ( shRNAs against PFKFB4 or SRC-3 compared to control non-targeting shRNA in MDA-MB231 cells. n = 3 biologically independent samples. **P < 0.01, ***P < 0.001, ****P < 0.0001, two-way ANOVA with Tukey's multiple comparisons test. b, Relative proliferation of MDA-MB-231 and MCF-7 cells 4 days after treatment with siRNA targeting GFP (control) or SRC-3 under the conditions indicated. Ade, adenine; Gua, guanine. n = 5 biologically independent replicates. ****P < 0.0001, one-way ANOVA with Tukey's multiple comparisons test. c, mRNA expression of metabolic enzymes TKT, XDH and AMPD1 in MDA-MB-231 cells after treatment with siRNAs targeting GFP (control), PFKFB4 or SRC-3. n = 3 biologically independent samples. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA with Tukey's multiple comparisons test. d, Immunoprecipitation (IP) of ATF4 from MDA-MB-231 cells grown in 5 mM or 25 mM glucose after treatment with PFKFB4 shRNA, SRC-3 shRNA, or non-targeting control shRNA, or after SRC-3 shRNA plus re-expression of SRC-3(Ser857Ala). Levels of pSRC-3-Ser857 associated with ATF4 were detected by immunoblotting. IgG light chain conjugated to horseradish peroxidase (HRP) was used to probe ATF4 in immunoblotting. The ATF4 blot was exposed for shorter (light) and longer (dark) time points to visualize faint bands. e, f, ChIP of ATF4, total SRC-3, and pSRC-3-S857 followed by qPCR from MDA-MB-231 cells treated with 5 mM or 25 mM glucose compared to an IgG isotype control. SRC-3 antibodies were either from BD Biosciences or Cell Signaling Technology. TKT (e) and AMPD1 (f) expression are shown. n = 3 biologically independent samples used for ChIP. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA with Tukey's multiple comparisons test compared to 5 mM glucose groups. See Source Data for exact P values. Unless stated otherwise, data are mean ± s.d.
After resecting out the primary tumours, we allowed the animals to survive for four more weeks with weekly bioluminescence imaging ( Fig. 4a) to evaluate metastatic potential. Animals with primary tumours expressing wild-type SRC-3 developed profound lung metastasis with morbid hunched back posture, whereas suppression of SRC-3 or PFKFB4 or expression of the SRC-3(Ser857Ala) phosphorylation-deficient mutant all showed markedly reduced lung lesions ( Fig. 4c and Extended Data Fig. 9f ). Pathological analysis identified only a few micro-metastatic lesions in the lungs of animals with SRC-3(Ser857Ala), or SRC-3-and PFKFB4-ablated primary tumours (Fig. 4d) , with no observed health issues during the four weeks after surgery. These findings demonstrate that SRC-3 and PFKFB4 are drivers of basal-subtype breast tumour growth and that phosphorylation of SRC-3 at the Ser857 site is crucial for metastatic progression of the disease. Immunostaining of the primary tumours with a pSRC-3-Ser857 antibody detected increased nuclear-localized human SRC-3 in the tumours collected from wild-type animals that progressed to aggressive metastatic disease, whereas PFKFB4-or SRC-3-ablated tumours had significantly reduced nuclear staining (Fig. 4e, f) . Nuclearlocalized pSRC-3-Ser857 represents active SRC-3 in the tumour that in turn promotes target gene expression to maintain tumour growth and metastasis. Importantly, this single phosphorylation site modification was also found to be an indicator of tumour metastasis mediated by ERK3 in a previous study 29 . Taken together, our data demonstrate that the PFKFB4-SRC-3 signalling axis promotes tumour cell proliferation by increasing purine synthesis (Extended Data Fig. 9g ), which may also serve as a critical determinant of metastatic progression of the disease.
To identify the clinical implications of this axis, we first analysed expression of PFKFB4 in The Cancer Genome Atlas (TCGA) database and found its expression to be significantly enhanced across all subtypes of breast cancer (Extended Data Fig. 9h ). Because SRC-3 is an ER coactivator, we analysed expression of pSRC-3-Ser857 and PFKFB4 in ER-positive primary breast tumours and adjacent normal tissues. Our data show increased levels of pSRC-3-Ser857, PFKFB4 and SRC-3 in most tumours compared to normal tissues (Extended Data Fig. 10a, b) , and a significant correlation between pSRC-3-Ser857 and PFKFB4 levels (r = 0.63, Extended Data Fig. 10c ). Because PFKFB4 expression is also increased in other breast tumour subtypes, we performed protein array analyses using MDA-MB-231 cell lysates with suppressed expression of SRC-3 or PFKFB4 protein, and compared the significantly altered protein targets to the control non-targeting shRNA. Our study identified a common proteomic signature by intersecting the significant proteins affected by 'both' SRC-3 and PFKFB4 knockdown (Extended Data Fig. 10d ). Imposing the restriction of protein-changes in the 'same direction' we evaluated the correlation of the common PFKFB4-SRC-3 proteomic signature with patient survival in a cohort of specimens from patients with breast cancer for which clinical information was available. We identified that the PFKFB4-SRC-3 common proteomic Letter reSeArCH signature also is associated with a decreased likelihood of survival in a basal-like-subtype triple-negative patient cohort (Extended Data  Fig. 10e ). These clinical associations are compatible with our in vivo experimental observations substantiating that the PFKFB4-SRC-3 axis is a molecular powerhouse that propels breast tumorigenesis leading it to an aggressive metastatic disease.
Here we have uncovered an interaction between the glycolytic pathway and the oncogenic activation of the transcriptional coactivator SRC-3. The Warburg effect is known to be one of the most dominant sugar metabolic pathways across cancers generating energy and macromolecules to sustain rapid proliferation and tumour growth. We now find that a glycolytic stimulator, the bifunctional enzyme PFKFB4, also can operate as a protein kinase, at least in actively glycolytic tumours. After glucose uptake, PFKFB4 catalyses the synthesis of F2,6BP from F6P and ATP; and our study revealed that under these conditions, PFKFB4 can also phosphorylate SRC-3 at Ser857. Phosphorylation of SRC-3 at Ser857 rapidly increases its transcriptional activity and promotes the synthesis of genes for driving glucose flux towards purine synthesis (Extended Data Fig. 10f) . The PFKFB4-SRC-3 axis was found to be enriched in ER-positive breast tumours, and was also identified to promote a common proteomic signature that correlates with worse outcomes in patients with triple-negative breast cancer, thereby driving an aggressive metastatic disease (Extended Data Fig. 10g ). Our work suggests that targeting the PFKFB4-SRC-3 axis may be therapeutically valuable in breast tumours that are notably dependent on glucose metabolism.
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Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0018-1. . The construct expressing the GAL4 responsive luciferase reporter (pG5-luc) was obtained from Promega, and the pBIND-SRC-3 construct was generated by inserting an in-frame fusion between the GAL4 DNAbinding domain and the open reading frame of human SRC-3, as previously described 12 . The pBIND-SRC-3(S857A) 31 and pBIND-SRC-3(S857E) mutant were generated using the QuikChange Lightening site-directed mutagenesis kit, as described earlier 31 . The GST-SRC-3 fragment constructs were obtained by cloning portions of the SRC-3 in-frame with GST. The N terminus bHLH (amino acids 1-320), serine/threonine (S/T) (amino acids 321-580), RID (amino acids 581-840), CID (amino acids 841-1080), and HAT (amino acids 1081-1421) domains were generated as previously described 7 . The expression plasmid encoding SRC-3 with a C-terminal Flag tag was cloned into pSG5-Flag (WT SRC-3), and the point mutation of serine 857 to alanine (Ser857Ala) was generated by site-directed mutagenesis of wild-type SRC-3 and GST-SRC-3-CID constructs 13, 29 . The human PFKFB4 cDNA (NM_004567.3) was obtained from Origene (RC201573). The PFKFB4 mutants Gly46Ala, Pro48Ala, Gly51Ala, Arg230Ala and Arg238Ala were generated by site-directed mutagenesis. All constructs were verified by Sanger sequencing. The siGENOME siRNA against PFKFB4, SRC-3 and ATF4 were obtained from Dharmacon.
The shRNA sequences were as follows: shPFK#09 (TRCN0000199909): 5 ′-CC GG GC TG AT TG GC TG CC AC AT TT CC TC GA GG AA AT GT GG CAGCCAATCA GCTTTTTTG-3′; shPFK#20 (TRCN0000199820): 5′-CCGGGCGCAGCTCTTA GGTGTTCACCTCGAGGTGAACACCTAAGAGCTGCGCTTTTTTG-3′; shSR C-3#21 (TRCN0000370321): 5′-CCGGTGACACTGCACTAGGATTATTCTCGA GAATAATCCTAGTGCAGTGTCATTTTTG-3′; shSRC-3#96 (TRCN00003 65196): 5′-C CG GTTCCACCTCCTAGGGATATAACTCGAGTTATATCCCTA GGAGGTGGAATTTTTG-3′. Cell culture. HeLa, HEK293T, MDA-MB-231, MCF-7 and MCF-7-ERE-MAR-Luc cells were cultured in DMEM (Gibco) supplemented with 10% FBS; SK-BR-3 cells were grown in McCoy's medium with 10% FBS; and MCF-10A cells in DMEM/ F12 (Gibco) supplemented with 5% horse serum, epidermal growth factor (EGF), hydrocortisone, cholera toxin and insulin. All cell lines were incubated at 37 °C and 5% CO 2 . Cell lines were obtained from ATCC, and maintained and yearly tested for mycoplasma contamination by the Tissue Culture Core, Baylor College of Medicine (BCM).
Stable cells expressing shRNAs were generated by lentiviral transduction in presence of polybrene (8 µg ml
−1
). Polyclonal pooled populations of stable cells were selected in the presence of puromycin (1 µg ml −1 ) for more than three passages before initiating any functional experiments. Human kinome library screen. A high-throughput RNAi screen was performed using the Stealth RNAi human kinase library (Life Technologies) targeting each 636 human kinases with three individual siRNAs directed at different regions of the gene that were arrayed in twenty-four 96-well plates. To identify the kinases that modulate SRC-3 transcriptional activity, we reverse co-transfected HeLa cells with pBIND or pBIND-SRC-3 (2 ng per 96-well) along with pG5luc firefly-luciferase reporter (100 ng per 96-well), and control siRNA targeting GFP (siGFP) or siRNAs targeting kinases (40 nM). The mixture was incubated with 0.75 µl per 96-well of Lipofectamine 2000 for 20 min followed by addition of HeLa cell suspension (12,500 cells per 96-well) in complete growth medium (DMEM plus 10% FBS) on top. After 48 h of culture, plates were carefully washed with PBS and luminescence reading was recorded in luminometer (Berthold) using the Dual-Luciferase Assay System (Promega). Additional wells present on all plates had appropriate controls containing cells transfected with pBIND and siRNA targeting GFP (siGFP), or pBIND-SRC-3 and siGFP along with reporter plasmid. SRC-3 transcriptional activity was calculated by comparing the relative luciferase units (RLU) of pBIND-SRC-3 to pBIND readings transfected with siGFP. Firefly luciferase reading from each well was normalized to its Renilla reading (pBIND-vector backbone contains the Renilla luciferase gene) to adjust the variations in transfection efficiency. The fold change in SRC-3 activity upon suppression of kinases was calculated by comparing data to siGFP readings, followed by robust z-score analysis to identify kinases that either increase or decrease SRC-3 activity more than 2 s.d. above or below control siGFP (pBIND-SRC-3 plus siGFP) treatment. Fold change values were converted to log 2 for each set of siRNA and then graphed in 3D plot. Cell proliferation assays. Cells were transfected with indicated siRNAs and were seeded at a density of 3,000 cells per 96-well in complete growth medium.
For rescue experiment, cells were seeded in complete growth medium supplemented with dialysed serum with or without purines (10 µM adenosine, Sigma and 10 µM guanosine, Sigma). After 4 days, cells were stained with CellTiter96 (Promega) reagent followed by measurement of absorbance at 490 nm. For the clonogenic survival assays, 1,000 cells per well were plated onto a 6-well plate, and were incubated for 7 days, and stained with crystal violet. The medium was changed every two days. In vitro phosphorylation assays. The full length SRC-3-Flag protein was expressed in Sf9 cells and purified using anti-Flag antibody beads 13 . The SRC-3 fragments were expressed as GST fusion proteins in Escherichia coli and purified using a GST fusion protein purification kit (Life Technologies) following the manufacturer's protocol. Each reaction of the in vitro phosphorylation assay was carried out with varying concentration of purified recombinant GST-PFKFB4 protein (SignalChem) (0.1-1 µg) along with SRC-3 (0.25 µg) as substrate, cold ATP (0.2 mM) or 5 µCi [γ-32 P]ATP (Perkin Elmer), and 1 × kinase buffer (Cell Signaling) in a total volume of 30 µl. The reaction was carried out at 30 °C for 30 min and then stopped by adding 10 µl of 4× SDS sample buffer. Proteins were resolved by SDS-PAGE gel, stained with Coomassie blue (Bio-Rad), and visualized by autoradiography or probed with anti-Ser/Thr antibody (BD Biosciences). For mass spectrometric (MS) identification of phosphorylation sites, the GST-SRC-3-CID protein was used as a substrate for the kinase reaction along with cold ATP and PFKFB4 enzyme followed by separation by SDS-PAGE and staining with Coomassie blue. Gel lanes were sliced into different bands and in-gel digested overnight at 37 °C with trypsin. After digestion, peptides were extracted twice in 200 µl of acetonitrile with re-suspension in 20 µl of 2% formic acid before second extraction, dried in a Savant SpeedVac, and dissolved in a 5% methanol, 0.1% formic acid solution. The samples were then subjected to mass spectrometry separation to detect phosphorylated residues. Cell culture treatment conditions, protein isolation and immunoblotting. For siRNA treatments, cells were lysed 72 h after transfection. Stable cells were grown until 80% confluency before protein was extracted. During nutritional stress conditions, stable cells were cultured in complete medium until 80% confluency, followed by a brief starvation (3 h) in glucose-free growth medium. Cells were then switched to glucose-free DMEM supplemented with 10% dialysed serum and 5 mM or 25 mM glucose, as indicated in the figures, for 24 h before cells were lysed. For glucose withdrawal, cells were cultured in 25 mM for 24 h and then switched to medium containing 5 mM glucose for an additional 6 h. For FBP treatment, glucose-starved cells were pre-treated with 10 µM streptolysin O (Sigma, S5265) to permeabilize the cells, followed by the addition of FBP (Santa Cruz, sc-214805) as previously described 19 . Immunoblotting was performed as previously described 30 . In brief, cells were lysed using NP-40 lysis buffer (Life Technologies) along with protease and phosphatase inhibitor cocktail (Millipore). Total protein was estimated using a BCA protein estimation kit (Pierce) and approximately 40 µg of proteins were separated by 4-12% Bis-Tris gels (Life Technology) and electroblotted onto nitrocellulose membranes using the iBlot system (Life Technology). Blots were blocked for 2 h at room temperature or overnight at 4 °C in 1 × TBS buffer (Biorad) supplemented with 0.1% Tween-20 (Sigma) and either 5% bovine serum albumin (BSA) or 5% non-fat dry milk (Biorad). Blots were incubated overnight at 4 °C with primary antibody diluted into TBST containing 1% BSA or 5% non-fat dry milk. Blots were subsequently washed three times for 10 min in TBST and incubated with secondary antibody coupled to HRP (Promega). Blots were washed as previously described, reacted with ECL reagents (Thermo Fisher Scientific) and detected by chemi-luminescence (UVP Biospectrum). Semi-quantitative levels of each band were analysed by densitometry using UVP Vision Works LS software, and the relative values normalized to actin are indicated numerically under each lane.
Antibodies used for immunoblotting in the study are: mouse monoclonal SRC-3 (611105, BD Biosciences), rabbit monoclonal SRC-3 (2126, Cell Signaling), Flag (F3165, Sigma-Aldrich), mouse phosphoSerine/Threonine (612548, BD Biosciences), rabbit PFKFB4 (137785 and 71622, Abcam), mouse PFKFB4 (TA500809, Origene), rabbit monoclonal ATF4 (11815, Cell Signaling), and β-actin conjugated to HRP (A3854, Sigma-Aldrich). The phospho-SRC-3 (Ser857) rabbit monoclonal antibody was cell culture supernatant produced from hybridoma generated by immunizing animals with a synthetic peptide containing phosphorylated Ser857 of human SRC-3. This antibody (Clone 10A6) was a gift from Cell Signaling Technology. Immunoprecipitations. 293 T cultured in 100 mm dishes until 80% confluency was transfected with Flag-SRC-3 followed by infection with adenovirus PFKFB4 (Signagen Laboratories). Twenty-four hours after infection, the medium was changed and cells were incubated overnight in different concentrations of glucose Letter reSeArCH supplemented with protease and phosphatase inhibitor cocktail (Millipore). For co-immunoprecipitations, lysates were precleared with control Protein A/G Agarose beads (Pierce). Five hundred micrograms of protein were then used for pull-down assays using monoclonal anti-Flag (F3165, Sigma) or anti-phosho-Ser/ Thr antibody (BD Biosciences) overnight. The beads were then captured, washed and immunoprecipitated proteins were eluted and subjected to immunoblotting, along with 2% input sample run in parallel. For ATF4 pull-down, anti-ATF4 (11815, Cell Signaling) was used at a 1:250 dilutions to pull down ATF4. Light-chain-specific anti-rabbit secondary antibody conjugated to HRP (Jackson Immunoresearch, 1:5,000) was used to detect ATF4 in immunoblotting following immunoprecipitation to avoid overlap with IgG-heavy chain Immunohistochemistry. Immunohistochemistry was performed as previously described 30 . Mouse monoclonal anti-human Ki-67 antibody MIB-1 (Dako) and rabbit monoclonal anti-phospho-SRC-3 (Ser857) (Cell Signaling) were used to stain the lung sections followed by anti-mouse or anti-rabbit Alexa-594 secondary antibody (Molecular Probes). Gene expression analyses. Total RNA was isolated from cancer cells or tumours using the RNeasy Kit (QIAGEN). Reverse transcription was carried out using a Superscript VILO cDNA synthesis kit (Invitrogen) according to the manufacturer's instructions. For gene expression analysis, qPCR was performed using the Taqman system (Roche) with sequence-specific primers and the Universal Probe Library (Roche). ACTB was used as an internal control. Melt curve analysis was performed to ensure that a single PCR product was produced in a given well. We used three biological replicates for each treatment group. Data were analysed using the comparative C t method (ΔΔC t ). Targeted TCA, glycolysis, PPP and nucleotide synthesis, and intermediary metabolite analysis using liquid chromatography-mass spectrometry. Sample preparation for mass spectrometric analysis: the metabolome extraction method described earlier was used for the cell lines in this study 30, 32 . In brief, cells were thawed at 4 °C and subjected to freeze-thaw cycles in liquid nitrogen three times to rupture the cell membrane. Following this, 750 µl of ice-cold methanol:water (4:1) containing 20 µl of spiked internal standard was added to each cell line. The cells were homogenized for 1 min (30 s pulse twice) and mixed with 450 µl of ice-cold chloroform and vortex mixed in a Multi-Tube Vortexer for 10 min. The resulting homogenate was mixed with 150 µl of ice-cold water and vortexed again for 2 min. The homogenate was incubated at −20 °C for 20 min and centrifuged at 4 °C for 10 min to partition the aqueous and organic layers. The aqueous and organic layers were separated and dried at 37 °C for 45 min in an Automatic Environmental Speed Vac system (Thermo Fisher Scientific). The aqueous extract was reconstituted in 500 µl of ice-cold methanol:water (50:50) and filtered through 3 kDa molecular filter (Amicon Ultracel-3K Membrane, Millipore Corporation) at 4 °C for 90 min to remove proteins. The filtrate was dried at 37 °C for 45 min in a speed vac and stored at −80 °C until mass spectrometry analysis. Before mass spectrometry analysis, the dried extract was re-suspended in 100 µl of methanol:water (50:50) containing 0.1% formic acid and analysed using multiple reaction monitoring (MRM).
Liquid chromatography-mass spectrometry HPLC analysis was performed using an Agilent 1290 series HPLC system equipped with a degasser, binary pump, thermostatted auto sampler and column oven (all from Agilent Technologies). The MRM-based measurement of relative metabolite levels were used for normal phase chromatographic separation. All samples were kept at 4 °C, and 5 µl of the sample was used for analysis. Separation of TCA, glycolysis and PPP-associated metabolites. The normal phase chromatographic separation was also used for targeted identification of metabolites. This analysis used solvents containing water (solvent A), with solvent A modified by the addition of 5 mM ammonium acetate (pH 9.9), and 100% acetonitrile (solvent B). The binary pump flow rate was 0.2 ml min −1 with a gradient spanning 80% B to 2% B over a 20-min period followed by 2% B to 80% B for a 5-min period and followed by 80% B for a 13-min time period. The flow rate was gradually increased during the separation from 0.2 ml min (30-37.99 min) and finally set at 0.2 ml min −1 (5 min). Metabolites were separated on a Luna Amino (NH2) column (4 µm, 100 A 2.1 × 150 mm, Phenominex) that was maintained in a temperature-controlled chamber (37 °C). All the columns used in this study were washed and reconditioned after every 50 injections. Ten microlitres was injected and analysed using a 6495 QQQ triple quadrupole mass spectrometer (Agilent Technologies) coupled to a 1290 series HPLC system via selected reaction monitoring (SRM). Metabolites were measured using negative ionization mode with an electrospray ionization (ESI) voltage of −3,500 eV, respectively. Approximately 9-12 data points were acquired per detected metabolite. Separation of nucleotides. For measurement of nucleotides and deoxy-nucleotides before mass spectrometry analysis, the dried extract was suspended in 50 µl of methanol:water (50:50) containing 0.1% formic acid. Samples were delivered to the MS via reverse phase chromatography using a RRHD SB-CN column (1.8 µm, 3.0 × 100 mm, Agilent Technologies) at 300 µl min −1 . The gradient spanned 2% B to 98% B over a 15-min period followed by 98% B to 2% B for a 1-min period. The gradient was continued for a 4-min time period to re-equilibrate the column. Buffers A and B consisted of 0.1% formic acid in water and acetonitrile, respectively. Ten microlitres was injected and analysed using a 6495 QQQ triple quadrupole mass spectrometer (Agilent Technologies) coupled to a 1290 series HPLC system via SRM. Metabolites were measured using positive ionization mode with an ESI voltage of 4000 eV, respectively. Approximately 9-12 data points were acquired per detected metabolite. Isotope labelling and profiling by targeted mass spectrometry. Glucose labelled with [6] [7] [8] [9] [10] [11] [12] [13] C]glucose and [U- 13 C]glucose were purchased from Cambridge Isotope Laboratories. MDA-MB231 cells were grown in 10-cm dishes in regular medium until 80% confluence, followed by brief (3 h) starvation and then addition of 25 mM of [6- 13 C]glucose supplemented with glucose-free DMEM medium with 10% dialysed FBS and 1% penicillin/streptomycin 33 . For [U- 13 C]glucose, cells were fed with steady-state isotope tracers for 48 h and medium was replaced 2 h before metabolome collection and/or isotope tracer addition. Culture medium was collected, cells were washed with PBS, counted, and snap-frozen in liquid nitrogen. Cells were scraped into a 0.5-ml mixture of 1:1 water:methanol, sonicated for 1 min (two 30-s pulses), and then mixed with 450 µl ice-cold chloroform. The resulting homogenate was then mixed with ice-cold water and vortexed again for 2 min. The homogenate was incubated at −20 °C and centrifuged at 4 °C for 10 min to partition the aqueous and organic layers. The aqueous and organic layers were combined and dried at 37 °C for 45 min in an automatic Environmental Speed Vac system (Thermo Fisher Scientific). The extract was reconstituted in a 500 µl solution of ice-cold methanol:water (1:1) and filtered through a 3-kDa molecular filter (Amicon Ultracel 3-kDa Membrane) at 4 °C for 90 min to remove proteins. The filtrate was dried at 37 °C for 45 min in a speed vacuum and stored at −80 °C until mass spectrometry analysis. Before MS analysis, the dried extract was resuspended in a 50 µl solution of methanol:water (1:1) containing 0.1% formic acid, and then analysed using MRM. Ten microlitres was injected and analysed using a 6490 QQQ triple quadrupole mass spectrometer (Agilent Technologies) coupled to a 1290 Series HPLC system via SRM. Metabolites were targeted in both positive and negative ion modes: the ESI voltage was 4,000 V in positive ion mode and -3,500 V in negative ion mode. Approximately 9-12 data points were acquired per detected metabolite. To target the TCA flux, the samples were delivered to the mass spectrometer via normal-phase chromatography using a Luna Amino column (4 µm, 100 A 2.1 × 150 mm). To target the fatty-acid flux, the samples were delivered to the mass spectrometer via reverse-phase chromatography using a Phenyl Hexyl column (3 µm, 100 A 2.1 × 150 mm). For 13 C-labelled experiments, SRM was performed for expected 13 C incorporation in various forms for targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS). Mass isotopomer distribution (MID) was calculated and corrected for natural abundance. Proximity ligation assay. Interaction between endogenous SRC-3 and PFKFB4 was detected using the PLA technique 34 using Duolink In situ Red Starter Kit Mouse/Rabbit (UO92101, Sigma) according to manufacturer's instructions. In brief, MDA-MB-231 cells were seeded in a 35-mm glass bottom culture dish (P35G-0-14C, MatTek Corporation), and after reaching 80% confluency, cells were fixed followed by blocking for 1 h using the Duolink Blocking Solution at 37 °C. Cells were then incubated in presence of primary antibodies: SRC-3 (rabbit monoclonal, Cell Signaling) and PFKFB4 (mouse monoclonal, Origene), either alone or in combination. After incubation, cells were washed and Duolink PLA PLUS and MINUS probes were added for 1 h at 37 °C. After washing off the unbound probes, cells were incubated first with the ligase enzyme followed by DNA polymerase enzyme to amplify the DNA circle. Finally, cells were mounted using Duolink In Situ Mounting Media with DAPI, and analysed by microscopy. Images were obtained using Zeiss Axio Observer A1 inverted microscope with N-Achroplan 100 × /1.25 oil lens, Zeiss MRC5 camera, and AxioVision Rel.4.8 software. Analysis of ATF4 and SRC-3 cistromes and motif analysis of ATF4-bound sequences. Owing to the lack of ATF4 and SRC-3 ChIP-seq datasets in breast cancer cell lines, we compared an in-house SRC-3 ChIP-seq dataset of mouse liver 26 , with previously published ATF4 ChIP-seq data in mouse embryonic fibroblasts 27 . Even though this comparison is less than ideal as SRC-3 and ATF4 ChIP-seq were performed in different tissues, the co-localization of SRC-3 and ATF4 cistromes even in different tissues, nevertheless, argues for an interplay between them, a finding subsequently confirmed by co-immunoprecipitation and ChIP-qPCR assay in human breast cancer cell lines. ATF4 binding motifs in the promoter regions of XDH, TKT and AMPD1 genes were discovered using the MISP (Motif-based Interval Screener with PSSM) toolbox in Galaxy Cistrome with a P value cut-off of 0.005. The consensus ATF4-binding motif used as input is TGATGCAA. ChIP. The following antibodies were used for ChIP: SRC-3 (Cell Signaling or BD Biosciences), ATF4 (Santa Cruz C-20, and 11815 Cell Signaling), pSRC-3-S857 (Cell Signaling), and rabbit IgG. ChIP assays were performed according to an EZ ChIP kit (Millipore) with some modification 35 . In brief, MDA-MB-231 cells were Letter reSeArCH grown in 15-cm dishes until 80% confluent. For glucose stimulation, cells were glucose-deprived for 3 h by incubating in glucose-free DMEM supplemented with 10% FBS, followed by 4 h stimulation with 5 mM or 25 mM glucose. Cells were cross-linked in 1% formaldehyde and quenched with 125 mM glycine. Chromatin was sheared by sonication using a Branson Sonifier, precleared with control IgG antibodies and agarose beads (Millipore), and then immunoprecipitated with IgG (control), SRC-3, pSRC-3-S857 and ATF4 antibodies. DNA fragments were eluted from beads followed by reverse-crosslinking and purified DNA was used in qPCR reactions using SYBR green (Applied Biosytems) to determine the promoter occupancy. Melt curve analysis was performed to verify all SYBR green reactions produced a single PCR product. Luciferase assays. Luciferase assays were performed from whole-cell lysates made in Cell Culture Lysis reagent (Promega) using the Luciferase Reporter Assay (Promega) and a Berthold 96-well plate reader. Luciferase values were normalized to the total protein level. Metabolomic phenotyping microarrays. Screening was performed using 96-well plate phenotype microarrays (Biolog) containing 88 different carbon substrates and 5 nucleotides as the energy source 21 . MCF10A cells were infected with adenovirus expressing GFP or SRC-3, and seeded at an initial density of 2 × 10 4 cells per well in triplicate. Biolog Redox Dye Mix MA was added to each well according to the manufacturer's instructions, and kinetic usage of the metabolites was monitored using the GEN III OmniLog ID System (Biolog). Human breast tumours. The breast tumours and adjoining normal tissue was obtained from the Lester and Sue Smith Breast Center at Baylor College of Medicine according to the Institutional Research Board approved protocol #H-7900. Whole-cell lysates from a total of 14 human breast tumours that are ER + primary tumours, along with matched normal tissues, were used to detect pSRC-3-Ser857, SRC-3, and PFKFB4 levels by immunoblotting. Determining a common PFKFB4-SRC-3 proteomic signature. Protein lysates from MDA-MB-231 cells stably expressing shRNAs targeting SRC-3 or PFKFB4 were used for protein array analysis as described before 36 . Expression of proteins significantly altered owing to the ablation of PFKFB4 and SRC-3 compared with non-targeting control shRNA were determined using a parametric t-test as implemented in the python (spicy) statistical system. Significance was assessed for P < 0.05, fold change exceeding 1.25 × , and normalized signal levels exceeding 200 U. A common proteomic signature was determined by intersecting the significant proteins affected by each treatment, and imposing the restriction that the protein changes are in the same direction. Association of the PFKFB4-SRC-3 proteomic signature in human basal breast cancer. We evaluated the association of the common PFKFB4-SRC-3 proteomic signature with patient survival in a cohort of primary basal breast cancer patient specimens collected by The Cancer Genome Atlas (TCGA) for which clinical information has been collected 37 . We first subsetted the proteins measured using the array by TCGA. Next, for each protein in the PFKFB4-SRC-3 common proteomic signature and for each basal breast cancer specimen, we computed the z-score for its expression within the patient cohort. We then computed the sum of the z-scores for each specimen. Specifically, the z-scores of the proteins suppressed by PFKFB4-SRC-3 (that is, upregulated by PFKFB4 and SRC-3 shRNA) were subtracted from the z-scores of the proteins induced by PFKFB4 (that is, downregulated by PFKFB4 and SRC-3 shRNA); this resulted in an activity score of the PFKFB4-SRC-3 common proteomic signature, respectively, for each specimen. After computing the activity scores, we further partitioned the patient cohort into specimens with a high activity score (top 33% of the specimens) and specimens with a low activity score (bottom 33% of the specimens) for the corresponding signatures.
We considered significant association with survival using the log-rank test (P < 0.05) and the Cox proportional hazard test (P < 0.05) available via the package survival as implemented in the R statistical system. Tumorigenicity and metastasis assays. All animal experiments were carried out in accordance with a protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee and experiments were terminated once maximal tumour volumes were reached (10% of the animal body weight). MDA-MB-231 breast cancer cells stably expressing luciferase were individually transduced with shRNAs targeting SRC-3 and PFKFB4. For the rescue experiment, SRC-3-ablated tumour cells were used to restore the levels of either wild-type SRC-3 or the SRC-3(Ser857Ala) mutant, and the polyclonal pooled population was selected. Approximately 2.5 × 10 5 cells were injected at orthotopic site along with Matrigel (BD Biosciences) (1:1 volume) in the mammary fat pad of 5-6 week-old female athymic nude Foxn1-nu mice (Envigo). The mammary tumour length (L) and width (W) were measured with a caliper. Tumour volumes were calculated using the formula L × W 2 × π/6. After six weeks, tumours were resected out by surgery and the animals were monitored for lung metastasis progression every week and quantified using noninvasive bioluminescence measurement with IVIS Lumina II equipment. Four weeks after tumour resection animals were euthanized and tissues were collected and fixed in 4% PFA. Paraffin-embedded lung samples were also subjected to haematoxylin and eosin staining to reveal the size and number of lung macro or micro-metastases. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. No statistical methods were used to predetermine sample size estimate. Statistics. Unless otherwise indicated, all results represent the mean ± s.d., and statistical comparisons between different groups were performed using the two-tailed Student's t-test, one-way or two-way ANOVA with appropriate multiple comparisons corrections. For all statistical analyses, differences of P ≤ 0.05 were considered statistically significant, and three biologically independent experiments with similar results are reported. GraphPad Prism software version 6.0/7.0 (GraphPad Software) was used for data analysis. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The ChIP-seq data have been submitted to the Gene Expression Omnibus under accessions GSE35681 (for ATF4) and is GSE67860 (for SRC-3). Other data that support the findings of this study are available from the corresponding author upon reasonable request. . n = 6 biological cell samples. **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired t-test two tailed. Boxes are as in Fig. 2e . e, f, Relative levels of intermediary metabolites in MDA-MB-231 cells after treatment with shRNAs targeting PFKFB4 or SRC-3 compared to control shRNA. e, Glycolytic and PPP metabolites. f, Nucleotides. n = 3 biological independent samples. *P < 0.05, two-way ANOVA with Tukey's multiple comparisons test. g, Total levels of purines in MCF10A cells transduced with with adenoviruses expressing GFP or SRC-3. n = 3 biological independent samples. *P < 0.05, ***P < 0.001, two-way ANOVA with Tukey's multiple comparisons test. See Source Data for exact P values. Unless stated otherwise, data are mean ± s.d.
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Extended Data Fig. 10 | The PFKFB4-SRC-3 axis drives transcriptional  programming in patients with breast cancer. a, b , Expression of pSRC-3, SRC-3 and PFKFB4 in ER + breast tumour specimens and matched adjoining normal tissues as detected by immunoblotting. n = 14 patients with ER + breast cancer. c, Semi-quantitative levels of bands shown in a and b, analysed by densitometry using UVP Vision Works LS software, and normalized relative to actin to calculate the fold change (tumour/ normal) and plotted to obtain the correlation between PFKFB4 and pSRC-3-Ser857 expression. n = 14 normal and tumour tissues. R = 0.63, P = 0.02 Spearman's rank correlation coefficient. d, log fold change in protein expression of the PFKFB4-SRC-3 signature compared to the control knockdown (non-targeting shRNA) as determined using a parametric t-test as implemented in the python (spicy) statistical system. Significance P < 0.05 and fold change exceeding 1.25× were used to classify true regulators of SRC-3 activity. n = 3 biologically independent samples. e, Kaplan-Meier survival plot showing poor survival of patients with breast cancer with basal subtype (triple-negative) disease exhibiting an increased expression of a common proteomic signature induced by the PFKFB4 and SRC-3 axis. The cohort of patients was collected by the TCGA. P = 0.0365, log-rank test; P = 0.02971, Cox proportional hazards, two-sided. f, Cartoon model describing the crosstalk between glycolysis and purine generation highlighting the essential steps regulated by pSRC-3-Ser857. This PFKFB4-dependent SRC-3 phosphorylation enhances mRNA expression of genes involved in purine metabolism driving breast tumour growth, proliferation and metastasis. AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AMP, adenosine monophosphate; F1,6-P, fructose 1,6 bisphosphate; IMP, inosine monophosphate. g, Model showing that, in glycolytic breast tumours, activated PFKFB4 drives SRC-3 phosphorylation at Ser857, which then activates ER-positive primary tumour growth in conjunction with E2-liganded ER, as well in ERnegative/recurrent tumours in conjunction with ATF4, driving aggressive metastatic disease. Data are mean ± s.d.
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Experimental design 1. Sample size
Describe how sample size was determined.
Statistical methods were not used to predetermine sample size (n). Number of sample was determined based on experimental approach, availability, feasibility required to obtain definitive results.
Data exclusions
Describe any data exclusions.
None.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Experiments reported are replicated at least twice with similar observations.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Majority of the experiments were performed following genetic manipulation of cells using shRNA/siRNA procedures or transfection of DNA plasmids. Similarly, animal experiments were performed with genetically manipulated cell lines. This design does not need randomization and recording the origin of samples are critical.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The researchers were not blinded during data collection/ or analysis. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Policy information about studies involving human research participants 12 . Description of human research participants Describe the covariate-relevant population characteristics of the human research participants. 
